|Bid||12.90 x 100|
|Ask||13.20 x 5000|
|Day's Range||11.80 - 13.45|
|52 Week Range||9.45 - 23.24|
|PE Ratio (TTM)||-9.94|
|Earnings Date||Oct 16, 2017 - Oct 20, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||16.73|
The biopharma successfully staved off a generic challenger for its most important drug.
Short interest is low for HZNP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold HZNP had net inflows of $560 million over the last one-month.
Q2 2017 Horizon Pharma PLC Earnings Call